IL159637A0 - Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells - Google Patents

Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells

Info

Publication number
IL159637A0
IL159637A0 IL15963702A IL15963702A IL159637A0 IL 159637 A0 IL159637 A0 IL 159637A0 IL 15963702 A IL15963702 A IL 15963702A IL 15963702 A IL15963702 A IL 15963702A IL 159637 A0 IL159637 A0 IL 159637A0
Authority
IL
Israel
Prior art keywords
cells
methods
hematopoietic progenitor
genetic modification
modified
Prior art date
Application number
IL15963702A
Other languages
English (en)
Original Assignee
Johnson & Johnson Res Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Res Pty Ltd filed Critical Johnson & Johnson Res Pty Ltd
Publication of IL159637A0 publication Critical patent/IL159637A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL15963702A 2001-07-10 2002-07-10 Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells IL159637A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30428301P 2001-07-10 2001-07-10
US30412701P 2001-07-10 2001-07-10
US34348401P 2001-12-21 2001-12-21
US38606302P 2002-06-04 2002-06-04
PCT/US2002/021907 WO2003006691A1 (en) 2001-07-10 2002-07-10 Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells

Publications (1)

Publication Number Publication Date
IL159637A0 true IL159637A0 (en) 2004-06-01

Family

ID=27501852

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15963702A IL159637A0 (en) 2001-07-10 2002-07-10 Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
IL159637A IL159637A (en) 2001-07-10 2003-12-29 Preparations @ for use @ in medicine @ genes that contain and transform cd34 + cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL159637A IL159637A (en) 2001-07-10 2003-12-29 Preparations @ for use @ in medicine @ genes that contain and transform cd34 + cells

Country Status (15)

Country Link
US (2) US7345025B2 (https=)
EP (2) EP2322618A1 (https=)
JP (2) JP5179697B2 (https=)
KR (1) KR101015913B1 (https=)
CN (2) CN101926824A (https=)
AT (1) ATE490322T1 (https=)
AU (1) AU2002316640C1 (https=)
BR (1) BR0211079A (https=)
CA (1) CA2453531A1 (https=)
DE (1) DE60238486D1 (https=)
DK (1) DK1414996T3 (https=)
IL (2) IL159637A0 (https=)
MX (1) MXPA04000268A (https=)
NZ (1) NZ530624A (https=)
WO (1) WO2003006691A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020058636A1 (en) * 1994-09-21 2002-05-16 Geoffrey P. Symonds Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
CA2279673A1 (en) * 1995-12-15 1997-06-16 Enzo Therapeutics, Inc. Property effecting and/or property exhibiting constructs for the expression of non-native nucleic acids for therapeutic and diagnostic uses
US6627442B1 (en) * 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
US7994144B2 (en) 2001-07-10 2011-08-09 Johnson & Johnson Research Pty, Limited Process for the preparation of a composition of genetically modified hematopoietic progenitor cells
CA2453187A1 (en) * 2001-07-10 2003-01-23 J & J Research Pty Ltd Production of transduced hematopoietic progenitor cells
JP5179697B2 (ja) 2001-07-10 2013-04-10 ジョンソン・アンド・ジョンソン・リサーチ・プロプライエタリー・リミテッド 造血前駆細胞を遺伝的に改変する方法及び改変された細胞の使用
US7737124B2 (en) 2001-09-13 2010-06-15 California Institute Of Technology Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
JP4344858B2 (ja) * 2001-09-13 2009-10-14 カリフォルニア インスティチュート オブ テクノロジー 細胞内で抗ウイルス性小ｒｎａ分子を発現させる方法
DE10212892A1 (de) * 2002-03-20 2003-10-09 Basf Plant Science Gmbh Konstrukte und Verfahren zur Regulation der Genexpression
DE10224750A1 (de) 2002-06-04 2003-12-24 Fresenius Medical Care De Gmbh Vorrichtung zur Behandlung einer medizinischen Flüssigkeit
WO2004071418A2 (en) * 2003-02-06 2004-08-26 Walter Reed Army Institute Of Research Compounds for the treatment of systemic lupus erythematosus
EP1613742A2 (en) * 2003-04-08 2006-01-11 YEDA RESEARCH AND DEVELOPMENT Co. LTD. Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same
GB0410130D0 (en) * 2004-05-06 2004-06-09 Molmed Spa Cell preparation
US7935074B2 (en) * 2005-02-28 2011-05-03 Fresenius Medical Care Holdings, Inc. Cassette system for peritoneal dialysis machine
US8197231B2 (en) 2005-07-13 2012-06-12 Purity Solutions Llc Diaphragm pump and related methods
US20070041948A1 (en) * 2005-07-20 2007-02-22 Seoul National University Industry Foundation Method for culturing and proliferating hematopoietic stem cells and progenitor cells using human endometrial cells
US20080038231A1 (en) * 2006-06-15 2008-02-14 Rodgerson Denis O Processing procedure for peripheral blood stem cells
JP2011160661A (ja) * 2008-06-02 2011-08-25 Kyowa Hakko Kirin Co Ltd 血球細胞の初期化法
US8112365B2 (en) * 2008-12-19 2012-02-07 Foster Scott C System and method for online employment recruiting and evaluation
US20100210989A1 (en) 2008-12-23 2010-08-19 Janet Lesley Macpherson Processing blood
US8192401B2 (en) 2009-03-20 2012-06-05 Fresenius Medical Care Holdings, Inc. Medical fluid pump systems and related components and methods
US20120034197A1 (en) * 2009-04-09 2012-02-09 Stemcyte Inc. Hiv-resistant stem cells and uses thereof
WO2011008858A1 (en) 2009-07-15 2011-01-20 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US8720913B2 (en) 2009-08-11 2014-05-13 Fresenius Medical Care Holdings, Inc. Portable peritoneal dialysis carts and related systems
WO2012074068A1 (ja) * 2010-12-01 2012-06-07 日産化学工業株式会社 ピラゾール化合物による造血幹細胞の製造方法
DE102010053973A1 (de) 2010-12-09 2012-06-14 Fresenius Medical Care Deutschland Gmbh Medizinisches Gerät mit einer Heizung
EP2654825B1 (en) 2010-12-20 2017-08-02 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US9624915B2 (en) 2011-03-09 2017-04-18 Fresenius Medical Care Holdings, Inc. Medical fluid delivery sets and related systems and methods
AU2012254069B2 (en) 2011-04-21 2015-10-08 Fresenius Medical Care Holdings, Inc. Medical fluid pumping systems and related devices and methods
US9186449B2 (en) 2011-11-01 2015-11-17 Fresenius Medical Care Holdings, Inc. Dialysis machine support assemblies and related systems and methods
US9610392B2 (en) 2012-06-08 2017-04-04 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US9500188B2 (en) 2012-06-11 2016-11-22 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
FI2892330T3 (fi) * 2012-09-07 2023-03-25 Univ Yale Geneettisesti muokattuja hiiriä ja menetelmiä niiden käyttämiseksi
MX377561B (es) * 2012-11-05 2025-03-10 Regeneron Pharma Animales no humanos genéticamente modificados y métodos de uso de los mismos.
AU2013353573B2 (en) * 2012-12-06 2019-01-17 Enlivex Therapeutics R&D Ltd Therapeutic apoptotic cell preparations, method for producing same and uses thereof
US9561323B2 (en) 2013-03-14 2017-02-07 Fresenius Medical Care Holdings, Inc. Medical fluid cassette leak detection methods and devices
US10117985B2 (en) 2013-08-21 2018-11-06 Fresenius Medical Care Holdings, Inc. Determining a volume of medical fluid pumped into or out of a medical fluid cassette
CN103471896A (zh) * 2013-09-09 2013-12-25 上海兰卫临床检验有限公司 革兰染色液质控品制备方法
WO2018201065A1 (en) * 2017-04-27 2018-11-01 Fred Hutchinson Cancer Research Center Therapeutic formulations containing cd34+ stem cells derived from negative selection
IL274632B2 (en) * 2017-11-15 2024-12-01 Weird Science Llc Methods and compositions for non-myeloablative bone marrow reconstitution

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC2115A1 (fr) 1987-12-15 1991-07-05 Gene Shears Pty Ltd Ribozynes
US5254678A (en) 1987-12-15 1993-10-19 Gene Shears Pty. Limited Ribozymes
US5866701A (en) 1988-09-20 1999-02-02 The Board Of Regents For Northern Illinois University Of Dekalb HIV targeted hairpin ribozymes
US4978514A (en) 1989-09-12 1990-12-18 Fuel Tech, Inc. Combined catalytic/non-catalytic process for nitrogen oxides reduction
US5225337A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
US5500357A (en) 1990-11-02 1996-03-19 Agency Of Industrial Science & Technology, Ministry Of International Trade & Industry RNA transcription system using novel ribozyme
EP0578776A4 (en) 1991-04-05 1995-04-12 Edison Animal Biotech Center INHIBITION OF A RETROVIRUS USING NON-ENCODING NUCLEIC ACIDS HYBRIDIZING ON ENCAPSIDATION SEQUENCES.
US5693535A (en) 1992-05-14 1997-12-02 Ribozyme Pharmaceuticals, Inc. HIV targeted ribozymes
US5525468A (en) 1992-05-14 1996-06-11 Ribozyme Pharmaceuticals, Inc. Assay for Ribozyme target site
US5911983A (en) 1992-06-26 1999-06-15 University Of Pittsburgh Gene therapy for Gaucher disease using retroviral vectors
RU94046396A (ru) 1992-06-29 1996-11-10 Джин Ширс Пти.Лтд. (AU) Нуклеиновая кислота, днк, вектор, способ получения растения или животного, способ получения клеток, способ создания животного, животное, трансгенное животное, трансгенное растение, плоды, черенки и семена, растительные клетки, способ вмешательства в репликацию вируса
DE69333930T8 (de) 1993-01-22 2007-02-22 The Regents Of The University Of Colorado, Boulder Lokalisierung von therapeutischen mitteln
IL108719A0 (en) 1993-02-25 1994-08-26 Ortho Pharma Corp Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them
WO1995004818A1 (en) 1993-08-06 1995-02-16 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting human immunodeficiency virus replication
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
ATE320487T1 (de) 1994-01-05 2006-04-15 Gene Shears Pty Ltd Ribozyme gegen eine hiv tat sequenz
US5712384A (en) * 1994-01-05 1998-01-27 Gene Shears Pty Ltd. Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
US20020058636A1 (en) 1994-09-21 2002-05-16 Geoffrey P. Symonds Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
JPH11514209A (ja) 1995-04-20 1999-12-07 カイロン コーポレイション 組換えレトロウイルス調製物による造血幹細胞の高効率エクスビボ形質導入
US5741706A (en) 1996-06-13 1998-04-21 Immusol, Incorporated Anti-HIV ribozymes
TWI239352B (en) 1997-07-23 2005-09-11 Takara Bio Inc Gene transfer method with the use of serum-free medium
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6060317A (en) 1998-08-11 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Method of transducing mammalian cells, and products related thereto
WO2000034495A2 (en) 1998-12-04 2000-06-15 City Of Hope A method of genetically modifying very primitive quiescent human hematopoietic stem cells
WO2000075291A2 (en) * 1999-06-08 2000-12-14 Novartis Ag Cells with enforced expression of bcl-xl
CA2418720A1 (en) 2000-09-13 2002-03-21 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
CA2433680A1 (en) 2000-12-28 2002-08-01 Gregory M Arndt Double-stranded rna-mediated gene suppression
CA2453187A1 (en) * 2001-07-10 2003-01-23 J & J Research Pty Ltd Production of transduced hematopoietic progenitor cells
JP5179697B2 (ja) 2001-07-10 2013-04-10 ジョンソン・アンド・ジョンソン・リサーチ・プロプライエタリー・リミテッド 造血前駆細胞を遺伝的に改変する方法及び改変された細胞の使用
US7994144B2 (en) 2001-07-10 2011-08-09 Johnson & Johnson Research Pty, Limited Process for the preparation of a composition of genetically modified hematopoietic progenitor cells
KR100646702B1 (ko) * 2001-08-16 2006-11-17 에스케이씨 주식회사 홀 및/또는 그루브로 형성된 화학적 기계적 연마패드

Also Published As

Publication number Publication date
CN101926824A (zh) 2010-12-29
NZ530624A (en) 2009-02-28
JP2010077125A (ja) 2010-04-08
EP2322618A1 (en) 2011-05-18
KR20040032852A (ko) 2004-04-17
EP1414996A1 (en) 2004-05-06
ATE490322T1 (de) 2010-12-15
JP2005528319A (ja) 2005-09-22
HK1065074A1 (en) 2005-02-08
DK1414996T3 (da) 2011-03-21
WO2003006691A1 (en) 2003-01-23
EP1414996A4 (en) 2007-03-28
CA2453531A1 (en) 2003-01-23
IL159637A (en) 2013-07-31
KR101015913B1 (ko) 2011-02-23
JP5179697B2 (ja) 2013-04-10
EP1414996B1 (en) 2010-12-01
US20080044394A1 (en) 2008-02-21
AU2002316640C1 (en) 2009-01-29
DE60238486D1 (de) 2011-01-13
US7345025B2 (en) 2008-03-18
MXPA04000268A (es) 2005-03-07
US20040072771A1 (en) 2004-04-15
BR0211079A (pt) 2005-08-30
AU2002316640B2 (en) 2008-06-12
US7776595B2 (en) 2010-08-17
CN1553963A (zh) 2004-12-08

Similar Documents

Publication Publication Date Title
IL159637A0 (en) Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
EP1196444B8 (en) Exendin-4 conjugates and their medical use
EA200600076A1 (ru) Композиции и способы увеличения активности теломеразы
EA200300536A1 (ru) Неограниченные соматические стволовые клетки (ussc), полученные из пуповинной крови человека
WO2004047747A3 (en) Compositions and methods for cell dedifferentiation and tissue regeneration
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
EP2172246A3 (en) Methods for Alzheimer's disease treatment and cognitive enhancement
DE69929232D1 (de) Virusähnliche partikel zur induktion von autoantikörpern
TR200201440T2 (tr) Biomedikal kullanım için radyum-223 hazırlanması
TN2010000237A1 (en) Novel compounds and compositions and methods of use
MY129263A (en) Vaccine composition
EP1790728A3 (en) Imaging, diagnosis and treatment of disease
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
AU2002303817A1 (en) Compositions and methods for treating or preventing convulsions or seizures
AU8180001A (en) Human growth hormone to stimulate mobilization of pluripotent hematopoietic stemcells
WO1999046371A3 (en) Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery
WO2004090095A3 (en) Generation of human regulatory t cells by bacterial toxins for the treatment of inflammatory disorders
WO2004009029A3 (en) Compositions and methods for treating and preventing infection
WO2003029432A3 (en) Human mesenchymal progenitor cell
WO2004110373A3 (en) Therapeutic vaccine compositions for the treatment of type 1 diabetes
DE60016567D1 (de) Makrophagenhaltige zusammensetzung mit antiinfektiösen und hematopoietischen eigenschaften sowie deren herstellungsmethode
WO2003044047A3 (en) Virulence proteins of the genus yersinia and uses thereof
AU3058300A (en) Novel cationic couplers and their use for oxidation dyeing
PL355292A1 (en) Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics
WO2006102643A3 (en) Stably transformed bone marrow-derived cells and uses thereof